理想(02015.HK)周銷量達6,500輛 本月冀挑戰更高銷量目標
理想汽車-W(02015.HK)公布,在6月26日至7月2日一周銷量達6,500輛,穩居中國新勢力品牌銷量榜首。理想汽車憑理想L7、理想L8、理想L9三款車型就超過了其他新勢力品牌全系車型銷量,持續領跑新勢力。
在中國市場豪華品牌銷量排行榜中,理想汽車位居第六。而6月理想汽車月度交付量首次突破3萬輛,成為繼奔馳、寶馬、奧迪和特斯拉(Tesla)(TSLA.US)之後,第五家月交付量突破3萬輛的豪華品牌,也是唯一一家月交付量超過3萬輛的中國豪華品牌。
公司指出,7月份將挑戰更高的銷量目標,成為更多家庭首選的豪華汽車品牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.